Cargando…

Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab

EGFR belongs to the ErbB family of receptor tyrosine kinases and is associated with worse prognosis in head and neck squamous cell carcinoma (HNSCC). Cetuximab is a monoclonal antibody to the extracellular domain of EGFR and inhibits its downstream actions via multiple mechanisms. Besides its proven...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Akshar N., Mehnert, Janice M., Kim, Sung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3791949/
https://www.ncbi.nlm.nih.gov/pubmed/24179404
http://dx.doi.org/10.4137/CMENT.S5129
_version_ 1782286777621413888
author Patel, Akshar N.
Mehnert, Janice M.
Kim, Sung
author_facet Patel, Akshar N.
Mehnert, Janice M.
Kim, Sung
author_sort Patel, Akshar N.
collection PubMed
description EGFR belongs to the ErbB family of receptor tyrosine kinases and is associated with worse prognosis in head and neck squamous cell carcinoma (HNSCC). Cetuximab is a monoclonal antibody to the extracellular domain of EGFR and inhibits its downstream actions via multiple mechanisms. Besides its proven efficacy in locally advanced and incurable HNSCC, cetuximab has the distinct advantage of having a relatively tolerable side effect profile and not potentiating radiation toxicity. Though therapies for advanced HNSCC are evolving, locoregional recurrence and/or distant metastases occur in a large percentage of patients. Though some patients can be salvaged with surgery or radiation therapy, the majority are incurable, and are treated palliatively with systemic therapy. In the setting of first line therapy for recurrent/metastatic HNSCC, the EXTREME trial provided level 1 evidence that cetuximab improves overall survival when combined with cisplatinum and 5 FU. Following progression on first line chemotherapy, several phase II trials suggest that cetuximab monotherapy is a reasonable choice in this setting. Future studies should concentrate on clinical and molecular markers that may allow more personalized approaches to treating HNSCC, and combining EGFR inhibitors with other agents in a synergistic approach.
format Online
Article
Text
id pubmed-3791949
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-37919492013-10-31 Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab Patel, Akshar N. Mehnert, Janice M. Kim, Sung Clin Med Insights Ear Nose Throat Expert Review EGFR belongs to the ErbB family of receptor tyrosine kinases and is associated with worse prognosis in head and neck squamous cell carcinoma (HNSCC). Cetuximab is a monoclonal antibody to the extracellular domain of EGFR and inhibits its downstream actions via multiple mechanisms. Besides its proven efficacy in locally advanced and incurable HNSCC, cetuximab has the distinct advantage of having a relatively tolerable side effect profile and not potentiating radiation toxicity. Though therapies for advanced HNSCC are evolving, locoregional recurrence and/or distant metastases occur in a large percentage of patients. Though some patients can be salvaged with surgery or radiation therapy, the majority are incurable, and are treated palliatively with systemic therapy. In the setting of first line therapy for recurrent/metastatic HNSCC, the EXTREME trial provided level 1 evidence that cetuximab improves overall survival when combined with cisplatinum and 5 FU. Following progression on first line chemotherapy, several phase II trials suggest that cetuximab monotherapy is a reasonable choice in this setting. Future studies should concentrate on clinical and molecular markers that may allow more personalized approaches to treating HNSCC, and combining EGFR inhibitors with other agents in a synergistic approach. Libertas Academica 2012-04-03 /pmc/articles/PMC3791949/ /pubmed/24179404 http://dx.doi.org/10.4137/CMENT.S5129 Text en © 2012 the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
spellingShingle Expert Review
Patel, Akshar N.
Mehnert, Janice M.
Kim, Sung
Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab
title Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab
title_full Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab
title_fullStr Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab
title_full_unstemmed Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab
title_short Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab
title_sort treatment of recurrent metastatic head and neck cancer: focus on cetuximab
topic Expert Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3791949/
https://www.ncbi.nlm.nih.gov/pubmed/24179404
http://dx.doi.org/10.4137/CMENT.S5129
work_keys_str_mv AT patelaksharn treatmentofrecurrentmetastaticheadandneckcancerfocusoncetuximab
AT mehnertjanicem treatmentofrecurrentmetastaticheadandneckcancerfocusoncetuximab
AT kimsung treatmentofrecurrentmetastaticheadandneckcancerfocusoncetuximab